L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial
Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G
Published in JAMA
Methodology
Randomised double-blind placebo-controlled trial of L-arginine up to 9 g/day for 6 months after acute myocardial infarction.
Key Findings
L-arginine did not improve vascular stiffness or ejection fraction and was associated with higher mortality, leading to early trial termination.
Conclusions
L-arginine supplementation is not beneficial and may be harmful after myocardial infarction in older patients.
Limitations
Older post-MI population; stopped early; may not generalise to stable angina.
Supplements Studied
L-arginine did not improve vascular stiffness or ejection fraction and was associated with higher mortality, leading to early trial termination.
Outcomes Measured
L-arginine did not improve vascular stiffness or ejection fraction and was associated with higher mortality post-infarction.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.